DCT

2:26-cv-06262

Incyte Corp v. Padagis Israel Pharma Ltd

Log In
Key Events
Amended Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 2:26-cv-06262, D.N.J., 06/16/2026
  • Venue Allegations: Venue is alleged to be proper because the defendant is an alien entity that may be sued in any judicial district. The complaint also notes that the District of New Jersey is a likely destination for the accused product and that the defendant has previously availed itself of the district by asserting counterclaims in other cases.
  • Core Dispute: Plaintiff alleges that Defendant's submission of an Abbreviated New Drug Application (ANDA) to seek FDA approval for a generic version of Plaintiff's Opzelura® (ruxolitinib) cream constitutes an act of infringement of three U.S. patents covering topical pharmaceutical formulations and methods of use.
  • Technical Context: The lawsuit concerns topical formulations of ruxolitinib, a Janus kinase (JAK) inhibitor, used for treating inflammatory and autoimmune skin disorders such as atopic dermatitis.
  • Key Procedural History: This action is the latest in a series of Hatch-Waxman litigations between the parties concerning generic versions of Opzelura®. The complaint references two prior consolidated suits involving different sets of Orange Book-listed patents for the same drug. The current suit was triggered by Defendant's Paragraph IV certifications against the three patents-in-suit, which issued in early 2026.

Case Timeline

Date Event
2010-05-21 Earliest Priority Date for '381 and '593 Patents
2019-09-05 Earliest Priority Date for '096 Patent
2023-09-21 Padagis sends First Paragraph IV Notice Letter (prior patents)
2023-11-02 Incyte files first Hatch-Waxman suit against Padagis (prior patents)
2025-04-22 Padagis sends Second Paragraph IV Notice Letter (prior patent)
2025-05-23 Incyte files second Hatch-Waxman suit against Padagis (prior patent)
2026-02-10 '381 Patent Issued
2026-03-03 '593 Patent Issued
2026-03-31 '096 Patent Issued
2026-04-15 Padagis sends Third Paragraph IV Notice Letter ('381 & '593 Patents)
2026-06-01 Padagis sends Fourth Paragraph IV Notice Letter ('096 Patent)
2026-06-16 First Amended Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 12,544,381 - "Topical Formulation for JAK Inhibitor"

  • Patent Identification: U.S. Patent No. 12,544,381, "Topical Formulation for JAK Inhibitor," issued February 10, 2026. Compl. ¶5

The Invention Explained

  • Problem Addressed: The patent addresses the need for improved topical formulations of Janus kinase (JAK) inhibitors to treat skin immune disorders like psoriasis ʼ381 Patent, col. 1:20-2:53 Existing treatments were insufficient, and a stable, easily applied formulation with good skin permeation characteristics was needed ʼ381 Patent, col. 2:45-53
  • The Patented Solution: The patent discloses an oil-in-water emulsion formulation containing the JAK inhibitor ruxolitinib ʼ381 Patent, abstract This specific type of formulation was found to have superior properties, including better appearance, spreadability, stability, and higher skin permeation compared to anhydrous ointments or water-in-oil emulsions ʼ381 Patent, col. 4:42-65 The manufacturing process for the formulation is detailed in a flowchart ʼ381 Patent, Fig. 1
  • Technical Importance: The invention provides a stable and effective topical delivery vehicle for a potent JAK inhibitor, enabling localized treatment of skin disorders and avoiding issues associated with systemic administration.

Key Claims at a Glance

  • The complaint alleges infringement of one or more of the patent's claims without specifying them Compl. ¶37 Independent claim 1 is representative of the patent's composition claims.
  • The essential elements of independent claim 1 include:
    • A pharmaceutical formulation for topical skin application, wherein the formulation is an oil-in-water emulsion;
    • Comprising from 35% to 65% by weight of water;
    • Comprising from 10% to 40% by weight of a mixture of specific oil components (petrolatum, C16-18 fatty alcohols, mineral oil, a triglyceride, and a silicone oil);
    • Comprising from 2% to 6% by weight of a mixture of a glyceryl fatty ester and a sorbitan fatty ester;
    • Comprising from 0.05% to 5% by weight of a polysaccharide;
    • Comprising from 10% to 35% by weight of a mixture of an alkylene glycol and a polyalkylene glycol;
    • Comprising 1.5% by weight on a free base basis of a specific ruxolitinib phosphoric acid salt; and
    • Wherein the oil-in-water emulsion has a pH of not greater than 3.6.
      '381 Patent, cl. 1

U.S. Patent No. 12,564,593 - "Topical Formulation for a JAK Inhibitor"

  • Patent Identification: U.S. Patent No. 12,564,593, "Topical Formulation for a JAK Inhibitor," issued March 3, 2026. Compl. ¶6

The Invention Explained

  • Problem Addressed: Similar to the '381 patent, the '593 patent addresses the need for stable and effective topical formulations of JAK inhibitors for treating skin disorders like psoriasis ʼ593 Patent, col. 1:25-2:53
  • The Patented Solution: The patent also describes an oil-in-water emulsion of ruxolitinib ʼ593 Patent, abstract The specification highlights that this formulation provides superior spreadability, stability, and skin permeation compared to other formulation types, such as anhydrous ointments ʼ593 Patent, col. 4:42-65 The manufacturing process is also illustrated via a flowchart ʼ593 Patent, Fig. 1
  • Technical Importance: The invention provides a stable and effective topical delivery vehicle for a potent JAK inhibitor, enabling localized treatment of skin disorders and avoiding issues associated with systemic administration.

Key Claims at a Glance

  • The complaint asserts infringement of one or more claims without specifying them Compl. ¶46 Independent claim 1 is representative.
  • The essential elements of independent claim 1 include:
    • A pharmaceutical formulation for topical skin application, wherein the formulation is an oil-in-water emulsion;
    • Comprising from 35% to 65% by weight of water;
    • Comprising from 10% to 40% by weight of a mixture of specific oil components (petrolatum, C16-18 fatty alcohols, mineral oil, a triglyceride, and a silicone oil);
    • Comprising from 2% to 6% by weight of a mixture of a glyceryl fatty ester and a sorbitan fatty ester;
    • Comprising from 0.05% to 5% by weight of a polysaccharide;
    • Comprising from 10% to 35% by weight of a mixture of an alkylene glycol and a polyalkylene glycol; and
    • Comprising from 0.5% to 1.5% by weight on a free base basis of a specific ruxolitinib phosphoric acid salt.
      '593 Patent, cl. 1

U.S. Patent No. 12,589,096 - "Ruxolitinib Formulation for Reduction of Itch in Atopic Dermatitis"

  • Patent Identification: U.S. Patent No. 12,589,096, "Ruxolitinib Formulation for Reduction of Itch in Atopic Dermatitis," issued March 31, 2026. Compl. ¶7
  • Technology Synopsis: The patent addresses the problem of itch (pruritus) associated with atopic dermatitis, a primary symptom that damages the skin and impairs quality of life '096 Patent, col. 1:45-58 The invention is a method for reducing this itch by administering a topical cream containing either 0.75% or 1.5% ruxolitinib twice daily '096 Patent, abstract
  • Asserted Claims: The complaint makes a general allegation of infringement Compl. ¶55 Claim 1 is the primary independent method claim.
  • Accused Features: Padagis's Proposed Generic Product is accused of infringing the method claims by seeking FDA approval for the same indications as Opzelura®, thereby inducing physicians and patients to perform the patented method of treatment Compl. ¶56

III. The Accused Instrumentality

  • Product Identification: The accused instrumentality is "Padagis's Proposed Generic Product," which is the subject of ANDA No. 218657 Compl. ¶17
  • Functionality and Market Context: The complaint alleges this product is a generic version of Incyte's Opzelura® (ruxolitinib) cream Compl. ¶1 The action is based on the submission of the ANDA itself, which seeks FDA approval to manufacture and sell this generic product prior to the expiration of the patents-in-suit Compl. ¶17 The complaint alleges that upon approval, Padagis will market the generic product for the same FDA-approved indications as Opzelura®, which include the topical treatment of mild to moderate atopic dermatitis and nonsegmental vitiligo Compl. ¶¶11-12 Compl. ¶23

IV. Analysis of Infringement Allegations

The complaint, filed under the Hatch-Waxman Act, alleges an act of infringement based on the submission of ANDA No. 218657 with a Paragraph IV certification Compl. ¶35 Compl. ¶44 Compl. ¶53 The complaint does not contain specific factual allegations mapping elements of the accused product to the patent claims. The infringement theory is based on the allegation that the product described in the ANDA is a generic equivalent of Opzelura® cream and will be marketed for the same FDA-approved indications, thereby infringing the asserted composition and method claims.

'381 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A pharmaceutical formulation for topical skin application, wherein the formulation is an oil-in-water emulsion Padagis's ANDA No. 218657 allegedly describes an oil-in-water cream formulation that is a generic version of Opzelura®. ¶35 col. 4:42-43
from 35% to 65% by weight of the formulation of water The Proposed Generic Product is alleged to contain water within the claimed range. ¶35 col. 5:50-52
from 10% to 40% by weight of the formulation of a mixture of petrolatum, C16-18 fatty alcohols, mineral oil, a triglyceride, and a silicone oil The Proposed Generic Product is alleged to contain an oil component mixture with constituents and amounts falling within the claimed scope. ¶35 col. 5:19-34
from 2% to 6% by weight of the formulation of a mixture of a glyceryl fatty ester and a sorbitan fatty ester The Proposed Generic Product is alleged to contain an emulsifier mixture with constituents and amounts falling within the claimed scope. ¶35 col. 5:56-59
from 0.05% to 5% by weight of the formulation of a polysaccharide The Proposed Generic Product is alleged to contain a polysaccharide stabilizing agent within the claimed range. ¶35 col. 7:12-15
from 10% to 35% by weight of the formulation of a mixture of an alkylene glycol and a polyalkylene glycol The Proposed Generic Product is alleged to contain a solvent mixture with constituents and amounts falling within the claimed scope. ¶35 col. 7:35-38
1.5% of by weight of the formulation on a free base basis of 1:1 (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile phosphoric acid salt The Proposed Generic Product is alleged to contain the specified concentration of the ruxolitinib phosphate salt. ¶35 col. 8:12-15
wherein the oil-in-water emulsion has a pH of not greater than 3.6 The Proposed Generic Product is alleged to have a pH that meets this limitation. ¶35 col. 23:61-64

'593 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A pharmaceutical formulation for topical skin application, wherein the formulation is an oil-in-water emulsion Padagis's ANDA No. 218657 allegedly describes an oil-in-water cream formulation that is a generic version of Opzelura®. ¶44 col. 4:42-43
from 10% to 40% by weight of the formulation of a mixture of petrolatum, C16-18 fatty alcohols, mineral oil, a triglyceride, and a silicone oil The Proposed Generic Product is alleged to contain an oil component mixture with constituents and amounts falling within the claimed scope. ¶44 col. 5:19-34
from 0.5%-1.5% of (R)-3-cyclopentyl-3-[4-(7H-pyrrolo [2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl] propanenitrile phosphoric acid salt by weight of the formulation on a free base basis The Proposed Generic Product is alleged to contain the ruxolitinib phosphate salt in a concentration falling within the claimed range. ¶44 col. 8:1-5
  • Identified Points of Contention:
    • Scope Questions: A central point of contention for the composition claims in the '381 and '593 patents will be whether the specific excipients and their concentrations in Padagis's Proposed Generic Product fall within the scope of the claimed mixtures and ranges (e.g., "mixture of petrolatum, C16-18 fatty alcohols..."). The definitions of these broad chemical categories will be critical.
    • Technical Questions: For the '381 patent, a key factual question will be whether Padagis's product has a "pH of not greater than 3.6" as required by claim 1. For the '593 patent, which claims a range of active ingredient concentration ("from 0.5%-1.5%"), infringement will depend on the specific concentration detailed in Padagis's ANDA, whereas the '381 patent claims a fixed "1.5%".

No probative visual evidence provided in complaint.

V. Key Claim Terms for Construction

Term: "oil-in-water emulsion"

  • Context and Importance: This term defines the fundamental structure of the claimed formulation. The patents-in-suit distinguish this structure from other formulations like anhydrous ointments or water-in-oil emulsions, attributing the invention's superior stability and skin permeation to its oil-in-water nature ('381 Patent, col. 4:42-65). The dispute will hinge on whether the defendant's product, as described in its ANDA, meets the definition of an "oil-in-water emulsion" as understood in the patent.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The term is not given a special definition, which may support using its plain and ordinary meaning as understood by a person of ordinary skill in the art. The specification states the emulsion comprises "water, an oil component, and an emulsifier component," which is a general description '381 Patent, col. 4:30-34
    • Evidence for a Narrower Interpretation: A party could argue the term should be limited by the specific examples provided, such as the detailed formulation in Table 2, which lists exact components and percentages '381 Patent, col. 19:51-20:53 The manufacturing process in Figure 1 could also be cited to argue for a more specific structural definition.

Term: "a mixture of petrolatum, C16-18 fatty alcohols, mineral oil, a triglyceride, and a silicone oil"

  • Context and Importance: This Markush group defines the "oil component" of the claimed composition in the '381 and '593 patents. Infringement requires the accused product to contain this specific combination of five classes of ingredients. Practitioners may focus on whether the defendant's specific chosen excipients for its oil phase fall within the scope of these terms (e.g., whether the defendant's chosen emollient qualifies as a "triglyceride" as used in the patent).
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The specification provides general definitions for some of these sub-components, such as defining "fatty alcohol" to include a list of examples like "stearyl alcohol, lauryl alcohol, palmityl alcohol, cetyl alcohol," and others '381 Patent, col. 13:30-41 This could support a broad reading of the group's scope.
    • Evidence for a Narrower Interpretation: A defendant might argue that the scope of the terms should be narrowed to the specific embodiments disclosed, such as "light mineral oil" and "medium chain triglycerides" as the respective mineral oil and triglyceride components '381 Patent, Table 2

Term: "pH of not greater than 3.6" '381 Patent, cl. 1

  • Context and Importance: This is a critical, definite limitation present in claim 1 of the '381 patent but absent from claim 1 of the '593 patent. Its construction, and whether the accused product meets it, will be dispositive for infringement of this claim. Practitioners may focus on this term because it presents a clear potential point of non-infringement if the defendant's formulation has a pH outside this range.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The patent does not provide a special definition for how pH is to be measured, which would support using a standard industry method understood by a person of ordinary skill in the art.
    • Evidence for a Narrower Interpretation: The specification includes stability data showing the pH of exemplary formulations over time, with values ranging from 3.1 to 3.6 '381 Patent, Table 6 A party could argue that this data contextually defines the term, for example, by requiring the pH to remain within this range throughout the product's shelf life, not just at the time of manufacture.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges induced infringement for all three patents-in-suit, stating that upon FDA approval, Padagis will intentionally encourage infringement by marketing its generic product with a label that instructs physicians and patients to use it for the patented indications Compl. ¶38 Compl. ¶47 Compl. ¶56 It further alleges contributory infringement on the basis that the product is especially adapted for infringing uses and has no substantial non-infringing use Compl. ¶39 Compl. ¶48 Compl. ¶57
  • Willful Infringement: The complaint does not use the word "willful" but alleges that Padagis has knowledge of the patents-in-suit based on written notices sent to Incyte Compl. ¶31 Compl. ¶33 It seeks a declaration that the case is "exceptional" and an award of attorneys' fees under 35 U.S.C. § 285, which is the typical mechanism for pursuing enhanced damages for willful or egregious infringement Compl., Prayer for Relief (J)

VII. Analyst's Conclusion: Key Questions for the Case

  • A central issue will be one of claim construction: how broadly will the court construe the terms defining the components of the formulation, such as the "mixture" of oils and the "polysaccharide"? The outcome will determine whether the specific excipients in Padagis's confidential ANDA formulation fall within the literal scope of the composition claims.
  • A key evidentiary question will be one of factual correspondence: does the product described in Padagis's ANDA meet the specific numerical limitation in claim 1 of the '381 patent requiring a "pH of not greater than 3.6"? This presents a potential bright-line distinction between infringement of the '381 patent and the '593 patent, which lacks this limitation.
  • The case will also turn on the scope of the method claims in the '096 patent. A primary question will be whether Padagis's proposed product label will inevitably lead physicians and patients to practice the claimed methods of reducing itch in patients with specific atopic dermatitis characteristics, thereby satisfying the requirements for inducement.
Loading Amended Complaint